These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 37915617)

  • 1. Evidence to Date: Clinical Utility of Tremelimumab in the Treatment of Unresectable Hepatocellular Carcinoma.
    Ahmed Z; Lee SS; Victor DW; Kodali S
    J Hepatocell Carcinoma; 2023; 10():1911-1922. PubMed ID: 37915617
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tremelimumab: A Review in Advanced or Unresectable Hepatocellular Carcinoma.
    France NL; Blair HA
    Target Oncol; 2024 Jan; 19(1):115-123. PubMed ID: 38236364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tremelimumab: First Approval.
    Keam SJ
    Drugs; 2023 Jan; 83(1):93-102. PubMed ID: 36571670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.
    Tümen D; Heumann P; Gülow K; Demirci CN; Cosma LS; Müller M; Kandulski A
    Biomedicines; 2022 Dec; 10(12):. PubMed ID: 36551958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors as Therapy to Down-Stage Hepatocellular Carcinoma Prior to Liver Transplantation.
    Katariya NN; Lizaola-Mayo BC; Chascsa DM; Giorgakis E; Aqel BA; Moss AA; Uson Junior PLS; Borad MJ; Mathur AK
    Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565184
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma.
    de Castria TB; Khalil DN; Harding JJ; O'Reilly EM; Abou-Alfa GK
    Future Oncol; 2022 Oct; 18(33):3769-3782. PubMed ID: 36399155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy and chimeric antigen receptor T-cell therapy in hepatocellular carcinoma.
    Uson Junior PLS; Liu AJ; Sonbol MB; Borad MJ; Bekaii-Saab TS
    Chin Clin Oncol; 2021 Feb; 10(1):11. PubMed ID: 33541088
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.
    Ahmed F; Onwumeh-Okwundu J; Yukselen Z; Endaya Coronel MK; Zaidi M; Guntipalli P; Garimella V; Gudapati S; Mezidor MD; Andrews K; Mouchli M; Shahini E
    World J Gastrointest Oncol; 2021 Nov; 13(11):1813-1832. PubMed ID: 34853653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of durvalumab plus tremelimumab as first-line therapy in patients with unresectable hepatocellular carcinoma.
    Liao W; Xu H; Hutton D; Wu Q; Yang Y; Feng M; Lei W; Bai L; Li J; Li Q
    Ther Adv Med Oncol; 2024; 16():17588359241274625. PubMed ID: 39301138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic Therapy in Advanced Hepatocellular Carcinoma: Patient Selection and Key Considerations.
    Storandt MH; Mahipal A; Tella SH; Kommalapati A; Jin Z
    J Hepatocell Carcinoma; 2022; 9():1187-1200. PubMed ID: 36471742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field.
    Doycheva I; Thuluvath PJ
    J Clin Exp Hepatol; 2019; 9(5):588-596. PubMed ID: 31695249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma.
    Kudo M
    Int J Clin Oncol; 2022 Jul; 27(7):1110-1119. PubMed ID: 35527313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancements in Immunotherapeutic Treatments for Hepatocellular Carcinoma: Potential of Combination Therapies.
    Zarlashat Y; Mushtaq H; Pham L; Abbas W; Sato K
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 38999940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular Carcinoma: Advances in Systemic Therapy.
    Selene II; Ozen M; Patel RA
    Semin Intervent Radiol; 2024 Feb; 41(1):56-62. PubMed ID: 38495258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
    Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
    J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Goals and targets for personalized therapy for HCC.
    Couri T; Pillai A
    Hepatol Int; 2019 Mar; 13(2):125-137. PubMed ID: 30600478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma.
    Lee MMP; Chan LL; Chan SL
    J Liver Cancer; 2023 Sep; 23(2):262-271. PubMed ID: 37589044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Durvalumab: an investigational agent for unresectable hepatocellular carcinoma.
    Maestri M; Pallozzi M; Santopaolo F; Cerrito L; Pompili M; Gasbarrini A; Ponziani FR
    Expert Opin Investig Drugs; 2022 Apr; 31(4):347-360. PubMed ID: 35072571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current status and future of targeted-immune combination for hepatocellular carcinoma.
    Hao L; Li S; Ye F; Wang H; Zhong Y; Zhang X; Hu X; Huang X
    Front Immunol; 2024; 15():1418965. PubMed ID: 39161764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-Line Systemic Therapies for Advanced Hepatocellular Carcinoma: A Systematic Review and Patient-Level Network Meta-Analysis.
    Fong KY; Zhao JJ; Sultana R; Lee JJX; Lee SY; Chan SL; Yau T; Tai DWM; Sundar R; Too CW
    Liver Cancer; 2023 Feb; 12(1):7-18. PubMed ID: 36872922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.